FOR IMMEDIATE RELEASE
West Lebanon, NH – M2S, Inc., a leader and innovator in 3D medical imaging technology, is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the nonprofit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.
“We are extremely excited about the opportunity to participate in the ARMI initiative,” said Charles D. Ladd, Imaging Operations Manager, M2S. “Our vast experience in generating highly detailed 3D models to support implantation, transplantation and rapid prototyping for research will play an important role in ARMI’s tissue and organ manufacturing efforts. When a patient requires a custom manufactured organ for transplantation, M2S can produce a 3D representation of the organ and surrounding structures as well as the template for the creation and printing of the organ.”
Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute on behalf of the Department of Defense.
The Advanced Regenerative Manufacturing Institute (ARMI) will receive nearly $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs. Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue biofabrication technology in order to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.
M2S offers individual patient anatomical evaluation for custom organ development and implantation. When a patient requires a custom manufactured organ for transplantation, M2S can, from a patient’s CT scan, produce a 3D representation of the structure and/or surrounding tissues and provide metrics for the printing and implantation of the organ. In addition, the company can offer database development for standardized implants to match varied physical characteristics. Using its repository of CT scans, M2S can develop a sizing standardization and a database such that organs can be created prior to need and appropriate selection can be quickly achieved. M2S also has registry experience that can be utilized for tracking outcomes of transplant patients to support continuous development in technology and techniques for biofabrication as well as core-laboratory services for investigational device exemption, pivotal, and post-approval studies.
“We need to develop 21st century tools for engineered tissue manufacturing that will allow these innovations to be widely available – similar to how a 15th century tool (the printing press) allowed knowledge to spread widely during the Renaissance,” said inventor Dean Kamen, ARMI’s chairman.
ARMI’s efforts are supported by forty-seven industrial partners, twenty six academic and academically affiliated partners, and fourteen government and nonprofit partners. The ARMI partnership continues to grow.
About M2S, Inc.
M2S is an undisputed leader in 3D anatomical modeling and surgical planning for cardiovascular device implantation and organ transplantation. For over 20 years, M2S has been developing state-of-the art 3D visualization software, morphological metrics system as well as physician performance and patient outcomes registries. M2S supports quality improvement in healthcare with clinical registries, data sharing and clinical trial services for industry to manage clinical information, reduce costs, and improve the quality of patient care.
Visit www.m2s.com for more information.
The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is the 12th Manufacturing USA Institute. It brings together a consortium of nearly 100 partners from across industry, government, academia and the nonprofit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI will work to organize the current fragmented domestic capabilities in tissue biofabrication technology to better position the U.S. relative to global competition. For more information on ARMI, please visit www.ARMIUSA.org.
Contact Name: Jennifer Correa
Company Name: M2S
Address: 12 Commerce Ave, West Lebanon, NH 03784
Email: [email protected]